Tags

Type your tag names separated by a space and hit enter

Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.
J Med Econ. 2010; 13(3):482-91.JM

Abstract

OBJECTIVE

To compare healthcare resource utilization and costs of postherpetic neuralgia (PHN) patients initiating lidocaine patch 5% (lidocaine patch) or oral gabapentin/pregabalin.

METHODS

Patients with PHN diagnosis, or herpes zoster diagnosis and ≥30 days PHN-recommended treatment were selected from de-identified Medicaid claims data from Florida, Iowa, Missouri, and New Jersey, 1999-2007. Patients initiated monotherapy with lidocaine patch or gabapentin/pregabalin after PHN diagnosis, had continuous eligibility 6 months before (baseline) and 6 months after (study period) medication index date, and were ≥18 years old. Lidocaine patch patients were matched to gabapentin/pregabalin patients based on their propensity to initiate treatment. Study period resource utilization and costs from a Medicaid perspective were compared between treatment groups using univariate analysis.

RESULTS

Matched patients were on average 61.3 years old, approximately 73% were women, and 55% had other painful conditions during the baseline period. 6-month per patient PHN-related prescription drug costs were similar for matched lidocaine patch (n=312) and gabapentin/pregabalin (n=312) patients ($854 vs. 820, p=0.75), while PHN-related medical costs appeared lower in the lidocaine patch group ($145 vs. 353, p=0.12). Furthermore, there were no statistically significant differences between treatment groups during the observation period in overall resource utilization, total prescription drug costs, and total medical costs per patient.

CONCLUSIONS

In spite of higher list prices, PHN patients treated with lidocaine patch cost no more than patients treated with gabapentin or pregabalin in terms of overall healthcare costs over the 6-month study period. The study suggests that PHN-related medical costs may be lower among lidocaine patch patients.

LIMITATIONS

Findings are based on a Medicaid sample and may not be generalizable to all PHN patients.

Authors+Show Affiliations

Analysis Group, Inc., Boston, MA 02199, USA. nkirson@analysisgroup.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20684669

Citation

Kirson, Noam Y., et al. "Comparing Healthcare Costs of Medicaid Patients With Postherpetic Neuralgia (PHN) Treated With Lidocaine Patch 5% Versus Gabapentin or Pregabalin." Journal of Medical Economics, vol. 13, no. 3, 2010, pp. 482-91.
Kirson NY, Ivanova JI, Birnbaum HG, et al. Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin. J Med Econ. 2010;13(3):482-91.
Kirson, N. Y., Ivanova, J. I., Birnbaum, H. G., Wei, R., Kantor, E., Puenpatom, R. A., Ben-Joseph, R. H., & Summers, K. H. (2010). Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin. Journal of Medical Economics, 13(3), 482-91. https://doi.org/10.3111/13696998.2010.506176
Kirson NY, et al. Comparing Healthcare Costs of Medicaid Patients With Postherpetic Neuralgia (PHN) Treated With Lidocaine Patch 5% Versus Gabapentin or Pregabalin. J Med Econ. 2010;13(3):482-91. PubMed PMID: 20684669.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin. AU - Kirson,Noam Y, AU - Ivanova,Jasmina I, AU - Birnbaum,Howard G, AU - Wei,Robert, AU - Kantor,Evan, AU - Puenpatom,R Amy, AU - Ben-Joseph,Rami H, AU - Summers,Kent H, PY - 2010/8/6/entrez PY - 2010/8/6/pubmed PY - 2011/6/10/medline SP - 482 EP - 91 JF - Journal of medical economics JO - J Med Econ VL - 13 IS - 3 N2 - OBJECTIVE: To compare healthcare resource utilization and costs of postherpetic neuralgia (PHN) patients initiating lidocaine patch 5% (lidocaine patch) or oral gabapentin/pregabalin. METHODS: Patients with PHN diagnosis, or herpes zoster diagnosis and ≥30 days PHN-recommended treatment were selected from de-identified Medicaid claims data from Florida, Iowa, Missouri, and New Jersey, 1999-2007. Patients initiated monotherapy with lidocaine patch or gabapentin/pregabalin after PHN diagnosis, had continuous eligibility 6 months before (baseline) and 6 months after (study period) medication index date, and were ≥18 years old. Lidocaine patch patients were matched to gabapentin/pregabalin patients based on their propensity to initiate treatment. Study period resource utilization and costs from a Medicaid perspective were compared between treatment groups using univariate analysis. RESULTS: Matched patients were on average 61.3 years old, approximately 73% were women, and 55% had other painful conditions during the baseline period. 6-month per patient PHN-related prescription drug costs were similar for matched lidocaine patch (n=312) and gabapentin/pregabalin (n=312) patients ($854 vs. 820, p=0.75), while PHN-related medical costs appeared lower in the lidocaine patch group ($145 vs. 353, p=0.12). Furthermore, there were no statistically significant differences between treatment groups during the observation period in overall resource utilization, total prescription drug costs, and total medical costs per patient. CONCLUSIONS: In spite of higher list prices, PHN patients treated with lidocaine patch cost no more than patients treated with gabapentin or pregabalin in terms of overall healthcare costs over the 6-month study period. The study suggests that PHN-related medical costs may be lower among lidocaine patch patients. LIMITATIONS: Findings are based on a Medicaid sample and may not be generalizable to all PHN patients. SN - 1941-837X UR - https://www.unboundmedicine.com/medline/citation/20684669/Comparing_healthcare_costs_of_Medicaid_patients_with_postherpetic_neuralgia__PHN__treated_with_lidocaine_patch_5_versus_gabapentin_or_pregabalin_ L2 - https://www.tandfonline.com/doi/full/10.3111/13696998.2010.506176 DB - PRIME DP - Unbound Medicine ER -